Silence Therapeutics Plc D
D
SLN
19.785
USD
0.13
(0.64%)
Market Closed
Last updated: · Delayed 15 min
Volume
80,019
EPS
-1
Div Yield
-
P/E
-15
Market Cap
1,230,686,830
Title: Silence Therapeutics Plc
Sector: Healthcare
Industry: Biotechnology
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.